A practical reference on pentadecapeptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-07. Anything still debated is marked as such rather than presented as settled.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
=== Collateral consequences === Some authors have suggested that the collateral consequences of criminal conviction are more serious than the legal penalties. In many cases, statutes do not require that convicts are informed of these consequences. Many felons cannot be employed by the federal government or work in government jobs, as they do not meet the standards to gain security clearance. Felons convicted of distributing or selling drugs may not enlist in the military. Certain states are financially incentivized to exclude criminals from access to public housing. All states receive less federal highway funding if they fail to revoke or suspend driver's licenses of drug-related felons. Collateral consequences, and felon disenfranchisement in particular, have historically been at least partially racially motivated.
== Third Ministry == On 12 February 2004, following the 2004 election, a ministry of 19 cabinet ministers and 6 parliamentary secretaries was sworn in. It served until the reconstitution of the Ministry on 28 July 2005 following the resignation of Deputy Premier Terry Mackenroth. On 3 March 2005, Liddy Clark resigned after an investigation to the Crime and Misconduct Commission into airfares given to Aboriginal activists to Palm Island following a riot there. Her position in the ministry was not filled, with her portfolio going to John Mickel.
==== Hypoxia/anoxia tolerance ==== Hypoxia/Anoxia tolerant ectotherms have shown unique strategies for surviving anoxia. Pond turtles, such as the painted turtle (Chrysemys picta bellii), will experience anoxia during winter while they overwinter at the bottom of frozen ponds. In their cardiac mitochondria, the reversing of Complex V, the usage of ATP, and the build-up of succinate are all prevented during anoxia. Crucian carps (Carassius carassius) also overwinter in frozen ponds and show no loss membrane potential in their cardiac mitochondria during anoxia, but this relies on complexes I and III to be active.
=== EC 1.1.98 With other, known, acceptors === EC 1.1.98.1: Now EC 1.1.9.1, alcohol dehydrogenase (azurin) EC 1.1.98.2: glucose-6-phosphate dehydrogenase (coenzyme-F420) EC 1.1.98.3: decaprenylphospho-β-D-ribofuranose 2-oxidase EC 1.1.98.3: decaprenylphospho-β-D-ribofuranose 2-dehydrogenase EC 1.1.98.4: F420H2:quinone oxidoreductase EC 1.1.98.5: secondary-alcohol dehydrogenase (coenzyme-F420) EC 1.1.98.6: ribonucleoside-triphosphate reductase (formate) EC 1.1.98.7: serine-type anaerobic sulfatase-maturating enzyme
Sources: en.wikipedia.org
=== Music therapy === A 2009 review found that 3 to 10 sessions of music therapy (when added to standard care) resulted in a noticeable improvement in depressive symptoms, with still greater improvement after 16 to 51 sessions. A 2017 cochrane systematic review found that music therapy added to the usual treatment of depression gives better outcome than the usual treatment alone: "The effect size translates to a difference of 9.8 points on the HAM-D". It also found that there is no significant difference between active and receptive music therapy comparing depression outcome. It is also important to note that music therapy is not associated with more or fewer adverse events than treatment as usual.
=== Sinai === Since at least the First Dynasty (3000 BCE) in ancient Egypt, and possibly before then, turquoise was used by the Egyptians and was mined by them in the Sinai Peninsula. This region was known as the Country of Turquoise by the native Monitu. There are six mines in the peninsula, all on its southwest coast, covering an area of some 650 km2 (250 sq mi). The two most important of these mines, from a historical perspective, are Serabit el-Khadim and Wadi Maghareh, believed to be among the oldest of known mines. The former mine is situated about 4 kilometres from an ancient temple dedicated to the deity Hathor. The turquoise is found in sandstone that is, or was originally, overlain by basalt. Copper and iron workings are present in the area. Large-scale turquoise mining is not profitable today, but the deposits are sporadically quarried by Bedouin peoples using homemade gunpowder. In the rainy winter months, miners face a risk from flash flooding; even in the dry season, death from the collapse of the haphazardly exploited sandstone mine walls may occur. The colour of Sinai material is typically greener than that of Iranian material but is thought to be stable and fairly durable. Often referred to as "Egyptian turquoise", Sinai material is typically the most translucent, and under magnification, its surface structure is revealed to be peppered with dark blue discs not seen in material from other localities.
Carbapenem-resistant Enterobacteriaceae (CRE) or carbapenemase-producing Enterobacteriaceae (CPE) are gram-negative bacteria that are resistant to the carbapenem class of antibiotics, considered the drugs of last resort for such infections. They are resistant because they produce an enzyme called a carbapenemase that disables the drug molecule. The resistance can vary from moderate to severe. Enterobacteriaceae are common gastrointestinal commensals and infectious agents. Experts fear CRE as the new "superbug". The bacteria can kill up to half of patients who get bloodstream infections. Tom Frieden, former head of the Centers for Disease Control and Prevention has referred to CRE as "Nightmare bacteria". Examples of enzymes found in certain types of CRE are KPC (Klebsiella pneumoniae carbapenemase) and NDM (New Delhi Metallo-beta-lactamase). KPC and NDM are enzymes that break down carbapenems and make them ineffective. Both of these enzymes, as well as the enzyme VIM (Verona Integron-Mediated Metallo-β-lactamase) have also been reported in Pseudomonas.
=== Large cap indices === Russell 1000 Index: The large-cap index of the top 1,000 stocks in the Russell 3000 Index. Russell Top 500 Index: Another large-cap index, consisting of the top 500 stocks in the Russell 1000 Index. Russell Top 200 Index: The mega-cap index of the very largest 200 stocks in the Russell 1000 Index. Russell Top 100 Index: Mega-cap index of the top 100 stocks in the Russell 1000 Index. Russell Top 50 Index: Measures the performance of the 50 largest mega-cap companies in the Russell 1000 Index. Russell Top 20 Index: Mega-cap index of the top 20 stocks in the Russell 1000 Index. Russell Top 10 Index: Mega-cap index of the top 10 stocks in the Russell 1000 Index.
== Function == The protein encoded by this gene is an adaptor protein which contains five LIM domains, or double zinc fingers. The protein is likely involved in integrin signaling through its LIM domain-mediated interaction with integrin-linked kinase, found in focal adhesion plaques. It is also thought to act as a bridge linking integrin-linked kinase to NCK adaptor protein 2, which is involved in growth factor receptor kinase signaling pathways. Its localization to the periphery of spreading cells also suggests that this protein may play a role in integrin-mediated cell adhesion or spreading.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.